Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhino-Conjunctivitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2017, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape. Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 7, 8, 1 and 1 respectively. Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Rhino-Conjunctivitis - Overview Rhino-Conjunctivitis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Rhino-Conjunctivitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Rhino-Conjunctivitis - Companies Involved in Therapeutics Development ALK-Abello A/S Allergopharma GmbH & Co KG Allergy Therapeutics Plc ASIT Biotech SA Astellas Pharma Inc Bial - Portela & Ca SA Faes Farma SA Griffin Discoveries BV HAL Allergy BV Laboratorios LETI SL Oxagen Ltd Rhino-Conjunctivitis - Drug Profiles Acaroid - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile Product Description Mechanism Of Action R&D Progress Allergovac - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-4070 - Drug Profile Product Description Mechanism Of Action R&D Progress bilastine - Drug Profile Product Description Mechanism Of Action R&D Progress gp-ASIT - Drug Profile Product Description Mechanism Of Action R&D Progress hdm-ASIT - Drug Profile Product Description Mechanism Of Action R&D Progress OC-2417 - Drug Profile Product Description Mechanism Of Action R&D Progress Pollinex Quattro Grass - Drug Profile Product Description Mechanism Of Action R&D Progress Pollinex Quattro Tree - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile Product Description Mechanism Of Action R&D Progress Timapiprant - Drug Profile Product Description Mechanism Of Action R&D Progress Rhino-Conjunctivitis - Dormant Projects Rhino-Conjunctivitis - Discontinued Products Rhino-Conjunctivitis - Product Development Milestones Featured News & Press Releases May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017 Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study May 18, 2014: BioTech Tools will be present at the EAACI congress Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Rhino-Conjunctivitis, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H1 2017 Rhino-Conjunctivitis - Pipeline by Allergopharma GmbH & Co KG, H1 2017 Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2017 Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H1 2017 Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H1 2017 Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H1 2017 Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H1 2017 Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2017 Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2017 Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H1 2017 Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H1 2017 Rhino-Conjunctivitis - Dormant Projects, H1 2017 Rhino-Conjunctivitis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
